BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

891 related articles for article (PubMed ID: 17009160)

  • 41. The addition of induction chemotherapy to preoperative, concurrent chemoradiotherapy improves tumor response in patients with esophageal adenocarcinoma.
    Malaisrie SC; Hofstetter WL; Correa AM; Ajani JA; Komaki RR; Rice DC; Vaporciyan AA; Walsh GL; Roth JA; Wu TT; Swisher SG
    Cancer; 2006 Sep; 107(5):967-74. PubMed ID: 16874819
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Reduced incidence of nodal micrometastasis after major response to neoadjuvant chemoradiation in locally advanced esophageal cancer.
    Prenzel KL; König A; Schneider PM; Schnickmann C; Baldus SE; Schröder W; Bollschweiler E; Dienes HP; Mueller RP; Izbicki JR; Hölscher AH
    Ann Surg Oncol; 2007 Feb; 14(2):954-9. PubMed ID: 17103071
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Impact of preoperative radiochemotherapy on postoperative course and survival in patients with locally advanced squamous cell oesophageal carcinoma.
    Mariette C; Piessen G; Lamblin A; Mirabel X; Adenis A; Triboulet JP
    Br J Surg; 2006 Sep; 93(9):1077-83. PubMed ID: 16779882
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemo-radiotherapy.
    Saigusa S; Mohri Y; Ohi M; Toiyama Y; Ishino Y; Okugawa Y; Tanaka K; Inoue Y; Kusunoki M
    Oncol Rep; 2011 Nov; 26(5):1069-74. PubMed ID: 21811761
    [TBL] [Abstract][Full Text] [Related]  

  • 45. p53 Mutation status predicts pathological response to chemoradiotherapy in locally advanced esophageal cancer.
    Makino T; Yamasaki M; Miyata H; Yoshioka S; Takiguchi S; Fujiwara Y; Nakajima K; Nishida T; Mori M; Doki Y
    Ann Surg Oncol; 2010 Mar; 17(3):804-11. PubMed ID: 19885698
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Neoadjuvant chemoradiation versus hyperfractionated accelerated radiotherapy in locally advanced rectal cancer.
    Ceelen W; Boterberg T; Pattyn P; van Eijkeren M; Gillardin JM; Demetter P; Smeets P; Van Damme N; Monsaert E; Peeters M
    Ann Surg Oncol; 2007 Feb; 14(2):424-31. PubMed ID: 17096057
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Long-term results of neoadjuvant radiochemotherapy in squamous carcinoma of the thoracic esophagus].
    Pedrazzani C; Laterza E; Pasini F; Grandinetti A; Bernini M; Giacopuzzi S; Zerman G; Tasselli S; Ruzzenente A; De Manzoni G
    Minerva Chir; 2005 Feb; 60(1):11-6. PubMed ID: 15902048
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Multimodality treatment for esophageal cancer: the role of surgery and neoadjuvant therapy.
    Makary MA; Kiernan PD; Sheridan MJ; Tonnesen G; Hetrick V; Vaughan B; Graling P; Elster E
    Am Surg; 2003 Aug; 69(8):693-700; discussion 700-2. PubMed ID: 12953828
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pretreatment serum hemoglobin level as a predictive factor of response to neoadjuvant chemotherapy in patients with locally advanced squamous cervical carcinoma: a preliminary report.
    Fuso L; Mazzola S; Marocco F; Ferrero A; Dompè D; Carus AP; Zola P
    Gynecol Oncol; 2005 Dec; 99(3 Suppl 1):S187-91. PubMed ID: 16185756
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Who profits from neoadjuvant radiochemotherapy for locally advanced esophageal carcinoma?
    Elsaleh H; Farrell JJ; Crane CH
    J Gastroenterol Hepatol; 2009 May; 24(5):708-10. PubMed ID: 19646012
    [No Abstract]   [Full Text] [Related]  

  • 51. American Joint Committee on Cancer staging system does not accurately predict survival in patients receiving multimodality therapy for esophageal adenocarcinoma.
    Rizk NP; Venkatraman E; Bains MS; Park B; Flores R; Tang L; Ilson DH; Minsky BD; Rusch VW;
    J Clin Oncol; 2007 Feb; 25(5):507-12. PubMed ID: 17290058
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [The value of postoperative arterial infusion chemotherapy in patients with T3 esophageal squamous carcinoma after radical surgery].
    Liu BD; Zhi XY; Xu QS
    Zhonghua Yi Xue Za Zhi; 2005 Mar; 85(9):586-9. PubMed ID: 15949351
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cyclin D1 is a possible predictor of sensitivity to chemoradiotherapy for esophageal squamous cell carcinoma.
    Samejima R; Kitajima Y; Yunotani S; Miyazaki K
    Anticancer Res; 1999; 19(6C):5515-21. PubMed ID: 10697609
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A simplified tumor regression grade correlates with survival in locally advanced rectal carcinoma treated with neoadjuvant chemoradiotherapy.
    Beddy D; Hyland JM; Winter DC; Lim C; White A; Moriarty M; Armstrong J; Fennelly D; Gibbons D; Sheahan K
    Ann Surg Oncol; 2008 Dec; 15(12):3471-7. PubMed ID: 18846402
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Squamous cell carcinoma of the oesophagus--impact of surgery within the therapeutic concept].
    Gockel I; Lang H
    Z Gastroenterol; 2010 May; 48(5):560-6. PubMed ID: 20449788
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Adjuvant chemotherapy with 5-fluorouracil and cisplatin in lymph node-positive thoracic esophageal squamous cell carcinoma.
    Lee J; Lee KE; Im YH; Kang WK; Park K; Kim K; Shim YM
    Ann Thorac Surg; 2005 Oct; 80(4):1170-5. PubMed ID: 16181835
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Neoadjuvant chemoradiotherapy for advanced squamous cell carcinoma of thoracic esophagus].
    Takahashi S; Sato Y; Kondo M; Kudo T; Shimokuni T; Maeda Y; Honnma S; Shinohara T; Kohashi S; Todo S
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):45-9. PubMed ID: 14750320
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Clinical evaluation of low-dose cisplatin and 5-fluorouracil as adjuvant chemoradiotherapy for advanced squamous cell carcinoma of the esophagus.
    Shimizu K; Hihara J; Yoshida K; Toge T
    Hiroshima J Med Sci; 2005 Sep; 54(3):67-71. PubMed ID: 16180698
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Multimodality treatment in the management of esophageal cancer: neoadjuvant chemoradiotherapy followed by transhiatal esophagectomy.
    Irwin JF; Waterfield W; Poussin-Rosillo H; Sardi A
    Md Med J; 1997 Oct; 46(9):471-76. PubMed ID: 9327648
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Overexpression of survivin mRNA is associated with a favorable prognosis following neoadjuvant radiochemotherapy in esophageal cancer.
    Warnecke-Eberz U; Hokita S; Xi H; Higashi H; Baldus SE; Metzger R; Brabender J; Bollschweiler E; Mueller RP; Dienes HP; Hoelscher AH; Schneider PM
    Oncol Rep; 2005 Jun; 13(6):1241-6. PubMed ID: 15870949
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 45.